

Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	// (YY	YY/MM/DD)

CHRONIC LEUKAEMIAS

DISEASE

Note: complete this form only if this diagnosis was the indication for the HCT/CT or if it was specifically requested. Consult the manual for further information.

Date of diagnosis: _ _ _ / _ / _ _ (YYYY/MM/DD)

Classification (WHO 2022):

Chronic myeloid leukaemia (CML)

Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) / Richter transformation

Prolymphocytic (PLL) and other chronic leukaemias



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Chronic Myeloid Leukaemias (CML)

CHROMOSOME ANALYSIS			
Describe results of all the analysi	s done before HCT/CT trea	tment	
Chromosome analysis done before HCT/CT treatment: No Yes: Output of analysis: Separate abnormalities Full karyotype Unknown			
	Copy and fill-in this	s section as often as n	ecessary.
If chromosome analysis was done: What were the results? Normal Abnormal: number of abnormalities present: Failed Date of chromosome analysis:11(YYYY/MM/DD) Unknown For abnormal results, indicate below whether the abnormalities were absent, present or not evaluated.			
t(9;22)	Absent	Present	☐ Not evaluated
Trisomy 8	Absent	Present	☐ Not evaluated
Extra Ph	Absent	Present	□ Not evaluated
i(17)	Absent	Present	☐ Not evaluated
-7/Del	Absent	Present	Not evaluated
3q26	Absent	Present	Not evaluated
Other; specify:	Absent	Present	
OR Transcribe the complete karyotype:			



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other
Treatment Date	// (YY	YY/MM/DE))

MOLECULAR MARKER ANALYSIS

Molecular markers analysis d	one before HCT/CT treatmen	nt:	
🗌 No			
🗌 Yes			
Unknown			
	Copy and fill-in this section	as often as necessary.	
If molecular marker analysis wa	s done:		
Date of molecular marker a	nalysis: / / / (YY	YY/MM/DD) □ Unknown	
		_	
Indicate below whether the mar	kers were absent, present or n	ot evaluated.	
ASXL1	Absent	Present	☐ Not evaluated
BCORL1	Absent	Present	☐ Not evaluated
BCR::ABL1	Absent	Present	☐ Not evaluated
CBFB-MYH11	Absent	Present	☐ Not evaluated
EZH2	Absent	Present	Not evaluated
IDH1	Absent	Present	☐ Not evaluated
IKZF1	Absent	Present	Not evaluated
KMT2D	Absent	Present	Not evaluated
RUNX1	Absent	Present	Not evaluated
SETD1B	Absent	Present	☐ Not evaluated
TET2	Absent	Present	Not evaluated
TP53	Absent	Present:	Not evaluated
	TP53	3 mutation type: Single	e hit
		🔲 Multi	hit
		🔲 Unkno	own
	—		
Other; specify	Absent	Present	

PREVIOUS THERAPIES (between diagnosis and HCT/CT)

Previous therapy lines before the HCT/CT/GT:

🗌 No	
Pres:	complete the "Treatment — non-HCT/CT/GT/IST" form
🗌 Unkn	own



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Chronic Lymphocytic Leukaemias (CLL)

DISEASE	
---------	--

Sub-Classification (WHO 2022):		
Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL)	
Richter transformation:		
Transformed from a previous known CLL: 🔲 No (primary Richter)		
	LL diagnosis: / / (YYYY/MM/DD)	
	· /	
Type of Richter transformation:		
☐ Other; specify:		
Richter transformation clonally related to CLL: No		
☐ Yes		
	_	
CHROMOSOME ANALYSIS	5	
Describe results of all the analysis done before HCT/CT treatment		
Chromosome analysis done before HCT/CT treatment:		
\square No		
☐ Yes: Output of analysis: ☐ Separate abnormalities ☐ Full kary	otype	
Unknown		
 Copy and fill-in this section as often as necessary.		
If chromosome analysis was done:		
What were the results?		
Normal		
Abnormal: number of abnormalities present:		
☐ Failed		
Date of chromosome analysis: / _ / (YYYY/MM/DD)	Linknown	
For abnormal results, indicate below whether the abnormalities were absent	t, present or not evaluated.	
Trisomy 12	🔲 Absent 📋 Present 📋 Not evaluated	
del(13q14)	🗌 Absent 📋 Present 📋 Not evaluated	
del(11q22-23)	Absent Present Not evaluated	
del(17p)	🗌 Absent 📋 Present 📋 Not evaluated	
Other; specify:	Absent Present	
OR Transcribe the complete karyotype:		



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other
Treatment Date _	//(YY	YY/MM/DE))

MOLECULAR MARKER ANALYSIS

Molecular markers analysis done before H	ICT/CT treatment:		
□ No			
Yes			
Unknown			
Сору	and fill-in this section as ofte	en as necessary.	
If molecular marker analysis was done:			
Date of molecular marker analysis: _	//(YYYY/MM/I	DD) 🗌 Unknown	
IGVH mutational status: Absent Present High risk subset? No Yes Indicate below whether the markers were absent, present or not evaluated.			
TP53	Absent	Present;	Not evaluated
	TP	53 mutation type: 🗌 Sir	ngle hit
		🗌 Mu	ılti hit
		🗌 Un	known
Other; specify:	Absent	Present	

PREVIOUS THERAPIES (between diagnosis and HCT/CT)

Previous therapy lines before the HCT/CT:

🗌 No

Yes:

complete the "Treatment — non-HCT/CT/GT/IST" form

Unknown



Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	//(YY	YY/MM/DD)

Prolymphocytic (PLL) and Other Chronic Leukaemias

DISEASE	
---------	--

Sub-Classification (WHO 2022): Prolymphocytic and other chronic leukaemias

T-prolymphocytic leukaemia (T-PLL)
Hairy cell leukaemia
Splenic B-cell lymphoma/leukaemia with prominent nucleoli (SBLPN)
Other chronic leukaemia; specify:

CHROMOSOME ANALYSIS - only applicable for T-PLL			
Describe results of all the analysis done before HCT/CT treatment			
Chromosome analysis done before HCT/CT treatment:			
 No Yes: output of analysis: Separate abnormalities Full karyotype Unknown 			
Copy and fill-in this section as often as necessary.			
If chromosome analysis was done: What were the results? Normal Abnormal: number of abnormalities present: Failed Date of chromosome analysis:II (YYYY/MM/DD) Unknown For abnormal results, indicate below whether the abnormalities were absent, present or not evaluated.			
inv(14)/ t(14;14)(q11;q32)	Absent Present Not evaluated		
del(14)(q12)	Absent Present Not evaluated		
t(11;14)(q23;q11)	Absent Present Not evaluated		
t(7;14)(q35;q32.1)	Absent Present Not evaluated		
t(X;14)(q35;q11)	Absent Present Not evaluated		
idic(8)(p11)	Absent Present Not evaluated		
del(17p)	Absent Present Not evaluated		
Other; specify:	Absent Present		
OR			
Transcribe the complete karyotype:			



Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	// (YY	YY/MM/DD)

IMMUNOPHENOTYPING

only applicable for T-PLL

Immunophenotype of T-cells at diagnosis:

Note: Terminal desoxynucleotidyl transferase (TdT) must be negative.

Indicate below whether the phenotypes were absent, present or not evaluated.

CD4+	Absent	Present	Not evaluated	Unknown
CD8+	Absent	Present	☐ Not evaluated	🔲 Unknown

Lymphocyte count at diagnosis: ______ 10⁹ cells/L D Not evaluated D Unknown

Was mantle cell lymphoma excluded at diagnosis?:

		No
--	--	----

☐ Yes; **method**: ☐ FISH on t(11;14)(q23;q11)

Cyclin D1 expression

- Both
- Other

Unknown